• Revenue up 3.1% to $3.89 million
• Net loss of $512,000 due to strategic investments
• Launched new Pharmx Marketplace platform

Pharmx Technologies Limited (ASX: PHX) has reported its financial results for the half-year ended 31 December 2025. Revenue from operations was $3,890,000, up 3% on the prior period. However, the company incurred a loss before tax from operations of $444,000 (H1 FY24: profit of $379,000) due to significant strategic initiatives and investments made during the period. These investments were primarily focused on the launch of the first phase of the new Pharmx Marketplace, which occurred during the half. To successfully complete the launch, the company increased investment in development resources, IT infrastructure, and marketing activities, leading to higher personnel, technology, and marketing costs. Despite the transition phase and intentional pause on onboarding and promotion of the old PharmXchange marketplace, underlying revenue still grew 3% on the prior comparable period. The net loss after income tax for the half-year was $512,000 (H1 FY24: profit of $155,000). The company remains profitable at an operating level, with the net loss driven by non-cash costs such as amortization and employee performance rights expense. Looking ahead, Pharmx remains focused on increasing the number of suppliers, driving pharmacy engagement, growing transaction volumes, and enhancing its analytics capabilities to continue improving healthcare through its technology platform.

The company expects continued revenue growth driven by an increasing customer base and enhanced engagement and utilization with those customers. The focus on innovation and investment will remain central to the strategy to ensure partners can continue to take advantage of Pharmx's position as the leading provider of ordering technology to the pharmacy industry across Australia and New Zealand.